{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:18:05Z","timestamp":1790338685587,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.blre.2017.01.002","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T05:32:36Z","timestamp":1486099956000},"page":"173-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters"],"prefix":"10.1016","volume":"31","author":[{"given":"Shawna T.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1179-5879","authenticated-orcid":false,"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.blre.2017.01.002_bb0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/tid.12542","article-title":"Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR; comparison with recipients of solid organ transplants","volume":"18","author":"Panagou","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0010","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","article-title":"Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation","volume":"95","author":"Broers","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0015","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0020","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/cid\/ciw370","article-title":"Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples","volume":"63","author":"Preiksaitis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0025","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.blre.2017.01.002_bb0035","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2013.10.003","article-title":"Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen","volume":"20","author":"Manjappa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00277-014-2190-1","article-title":"Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia","volume":"94","author":"Jang","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2017.01.002_bb0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/338624","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection","volume":"185","author":"Nichols","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0055","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.bbmt.2014.08.010","article-title":"Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review","volume":"20","author":"Sousa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0060","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1016\/j.transproceed.2011.08.104","article-title":"Immunoglobulin prophylaxis against cytomegalovirus infection in patients at high risk of infection following allogeneic hematopoietic cell transplantation","volume":"43","author":"Ichihara","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.blre.2017.01.002_bb0065","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0070","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bbmt.2011.10.037","article-title":"Risk factors for progression from cytomegalovirus viremia to cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Jang","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1121","key":"10.1016\/j.blre.2017.01.002_bb0075","first-page":"e9","article-title":"Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.blre.2017.01.002_bb0080","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/tid.12456","article-title":"Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration","volume":"17","author":"Takahata","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"Management of cytomegalovirus infection in haemopoietic stem cell transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2017.01.002_bb0090","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bbmt.2010.07.026","article-title":"An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients","volume":"17","author":"Pollack","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0095","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcv.2015.11.033","article-title":"Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: development of multidrug resistance in the absence of anti-viral cellular immunity","volume":"74","author":"Herling","year":"2016","journal-title":"J Clin Virol"},{"key":"10.1016\/j.blre.2017.01.002_bb0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.bmt.1702526","article-title":"CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy","volume":"26","author":"Machado","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0110","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1469-0691.2008.02106.x","article-title":"Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study","volume":"14","author":"Torres","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.blre.2017.01.002_bb0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/civ215","article-title":"Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices","volume":"61","author":"Erard","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0120","first-page":"209","article-title":"Cytomegalovirus pneumonia: presentation, diagnosis, and treatment","volume":"10","author":"Ljungman","year":"1995","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.blre.2017.01.002_bb0125","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.bmt.1702877","article-title":"Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients","volume":"27","author":"Konoplev","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0130","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/gut.2005.087031","article-title":"Endoscopic evaluation for cytomegalovirus enterocolitis after allogeneic haematopoietic stem cell transplantation","volume":"55","author":"Kakugawa","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.blre.2017.01.002_bb0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbmt.2014.10.004","article-title":"Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease","volume":"21","author":"Bhutani","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0140","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00277-012-1632-x","article-title":"Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy","volume":"92","author":"Cho","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2017.01.002_bb0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1399-3062.2007.00241.x","article-title":"Clinical features and outcomes of cytomegalovirus retinitis after transplantation","volume":"10","author":"Eid","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0150","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1086\/318447","article-title":"Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation","volume":"32","author":"Crippa","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.blre.2017.01.002_bb0155","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3904\/kjim.2015.079","article-title":"Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy","volume":"31","author":"Kim","year":"2016","journal-title":"Korean J Int Med"},{"key":"10.1016\/j.blre.2017.01.002_bb0160","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/bmt.2010.35","article-title":"CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency","volume":"45","author":"Reddy","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0165","article-title":"Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2017.01.002_bb0170","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1128\/JVI.00870-09","article-title":"Liver sinusoidal endothelial cells are a site of murine cytomegalovirus latency and reactivation","volume":"83","author":"Seckert","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2017.01.002_bb0175","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00428-013-1528-8","article-title":"Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell transplantation","volume":"464","author":"Stift","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.blre.2017.01.002_bb0180","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/lt.500030513","article-title":"Cytomegalovirus infection, fulminant hepatitis, and liver transplantation: the sides of the triangle","volume":"3","author":"Samuel","year":"1997","journal-title":"Liver Transpl Surg"},{"key":"10.1016\/j.blre.2017.01.002_bb0185","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood.V67.4.1162.1162","article-title":"Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease","volume":"67","author":"Miller","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0190","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","article-title":"Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease","volume":"16","author":"Cantoni","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0195","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.V97.4.867","article-title":"Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes","volume":"97","author":"Nichols","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0200","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2012-12-470872","article-title":"HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion","volume":"122","author":"Stevanovic","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0205","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.bbmt.2012.06.017","article-title":"Alloreactive effector T cells require the local formation of a proinflammatory environment to allow crosstalk and high avidity interaction with nonhematopoietic tissues to induce GVHD reactivity","volume":"18","author":"van der Zouwen","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.bmt.1702459","article-title":"Evaluation of CMV\/human herpes virus-6 positivity in bronchoalveolar lavage fluids as early detection of acute GVHD following BMT: evidence of a significant relationship","volume":"26","author":"Takemoto","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0215","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.bmt.1704369","article-title":"Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation","volume":"33","author":"Mori","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0220","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2012.45.0247","article-title":"Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation","volume":"31","author":"Storb","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2017.01.002_bb0225","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood-2014-07-589150","article-title":"CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status","volume":"125","author":"Sellar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0230","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2141.1986.tb07551.x","article-title":"Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection","volume":"63","author":"Lonnqvist","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2017.01.002_bb0235","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0240","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2015.09.006","article-title":"Effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic stem cell transplantation in pediatric acute leukemia","volume":"22","author":"Inagaki","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0245","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","article-title":"Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients","volume":"118","author":"Elmaagacli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0250","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0255","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","article-title":"Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function","volume":"119","author":"Foley","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0260","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fimmu.2013.00458","article-title":"Impact of HCMV infection on NK cell development and function after HSCT","volume":"4","author":"Della Chiesa","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2017.01.002_bb0265","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.immuni.2004.11.012","article-title":"Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I","volume":"22","author":"Scotet","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2017.01.002_bb0270","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2010-01-255166","article-title":"The role of Vdelta2-negative gammadelta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation","volume":"116","author":"Knight","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0275","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood-2011-02-339135","article-title":"Differentiation of human peripheral blood Vdelta1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells","volume":"118","author":"Correia","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0280","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/leu.2012.374","article-title":"GammadeltaT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia","volume":"27","author":"Scheper","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2017.01.002_bb0285","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0290","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.bmt.1705140","article-title":"Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time","volume":"36","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0295","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1046\/j.1365-2141.2001.02849.x","volume":"113","author":"Kroger","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2017.01.002_bb0300","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2017.01.002_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Int Med"},{"key":"10.1016\/j.blre.2017.01.002_bb0310","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/375743","article-title":"Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus","volume":"188","author":"Chou","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0315","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/342385","article-title":"Ganciclovir-resistant cytomegalovirus in organ transplant recipients","volume":"35","author":"Limaye","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0320","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jcv.2006.11.005","article-title":"Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients","volume":"38","author":"Marfori","year":"2007","journal-title":"J Clin Virol"},{"key":"10.1016\/j.blre.2017.01.002_bb0325","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transpl"},{"key":"10.1016\/j.blre.2017.01.002_bb0330","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/tid.12311","article-title":"The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations","volume":"16","author":"Choi","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0335","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/JCM.41.1.187-191.2003","article-title":"Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients","volume":"41","author":"Li","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.blre.2017.01.002_bb0340","first-page":"157","article-title":"Comparison of real-time PCR and pp65 antigen assays for monitoring the development of cytomegalovirus disease in recipients of solid organ and bone marrow transplants","volume":"34","author":"Marchetti","year":"2011","journal-title":"New Microbiol"},{"key":"10.1016\/j.blre.2017.01.002_bb0345","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0350","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0355","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12185-008-0249-2","article-title":"Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients","volume":"89","author":"Takenaka","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2017.01.002_bb0360","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2005-09-3786","article-title":"Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation","volume":"107","author":"Einsele","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0365","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0370","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/367836","article-title":"Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"36","author":"Winston","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0375","doi-asserted-by":"crossref","first-page":"874601","DOI":"10.1155\/2012\/874601","article-title":"Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation","volume":"2012","author":"Barkam","year":"2012","journal-title":"Bone Marrow Res"},{"key":"10.1016\/j.blre.2017.01.002_bb0380","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jcv.2005.02.009","article-title":"Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation","volume":"34","author":"Cesaro","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1016\/j.blre.2017.01.002_bb0385","first-page":"4560745","article-title":"Treatment of cytomegalovirus infection with cidofovir and CMV immune globulin in a lung transplant recipient","volume":"2016","author":"Wilkens","year":"2016","journal-title":"Case Rep Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0390","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1399-3046.2008.01070.x","article-title":"Cytomegalovirus encephalitis\/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet","volume":"13","author":"Hubacek","year":"2009","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0395","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0400","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1592\/phco.30.6.554","article-title":"Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"30","author":"Alexander","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.blre.2017.01.002_bb0405","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/bbmt.2002.v8.pm11939601","article-title":"Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation","volume":"8","author":"Sokos","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0410","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006501.pub2","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation","volume":"4","author":"Raanani","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2017.01.002_bb0415","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","article-title":"Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Raanani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2017.01.002_bb0420","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1701113","volume":"21","author":"Ljungman","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0425","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0430","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.blre.2017.01.002_bb0435","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0440","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3851\/IMP1899","article-title":"Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients","volume":"17","author":"van der Beek","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.blre.2017.01.002_bb0445","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.bbmt.2007.08.049","volume":"13","author":"van Burik","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0450","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2009-09-244145","article-title":"Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis","volume":"115","author":"Brown","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0455","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1182\/blood-2011-06-361618","article-title":"Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients","volume":"118","author":"Milano","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0460","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.bmt.1705699","article-title":"Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies","volume":"40","author":"Ozdemir","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0465","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0470","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1128\/AAC.46.9.2969-2976.2002","article-title":"Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding","volume":"46","author":"Lalezari","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.blre.2017.01.002_bb0475","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1517\/14712598.2014.908847","article-title":"Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update","volume":"14","author":"Sellar","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.blre.2017.01.002_bb0480","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbmt.2014.11.002","article-title":"Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies","volume":"21","author":"Boeckh","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0485","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.blre.2017.01.002_bb0490","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2017.01.002_bb0495","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2017.01.002_bb0500","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.blre.2017.01.002_bb0505","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2017.01.002_bb0510","unstructured":"Marty FM. http:\/\/ir.chimerix.com\/releasedetail.cfm?ReleaseID=955952 (Accessed 5\/4\/2016). 2016."},{"key":"10.1016\/j.blre.2017.01.002_bb0515","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/vaccines1040398","article-title":"Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial","volume":"1","author":"Smith","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.blre.2017.01.002_bb0520","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0525","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1080\/21645515.2016.1164376","article-title":"Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus","volume":"12","author":"Finnefrock","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.blre.2017.01.002_bb0530","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3026(15)00246-X","article-title":"Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial","volume":"3","author":"Nakamura","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2017.01.002_bb0535","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1128\/AAC.02698-15","article-title":"A first-in-human study to assess the safety and pharmacokinetics of monoclonal antibodies against human cytomegalovirus in healthy volunteers","volume":"60","author":"Dole","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.blre.2017.01.002_bb0540","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.1016\/j.vaccine.2015.10.078","article-title":"A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells","volume":"33","author":"McVoy","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.blre.2017.01.002_bb0545","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1128\/JVI.78.18.10023-10033.2004","article-title":"Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes","volume":"78","author":"Hahn","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2017.01.002_bb0550","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2017.01.002_bb0555","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2017.01.002_bb0560","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.blre.2017.01.002_bb0565","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0570","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1086\/648422","article-title":"Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation","volume":"49","author":"Peggs","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2017.01.002_bb0575","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0580","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0585","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2017.01.002_bb0590","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2017.01.002_bb0595","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2146\/ajhp090424","article-title":"Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection","volume":"67","author":"Jacobsen","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.blre.2017.01.002_bb0600","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/infdis\/jis107","article-title":"Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant","volume":"205","author":"La Rosa","year":"2012","journal-title":"J Infect Dis"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16300492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16300492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T17:07:18Z","timestamp":1601572038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X16300492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":120,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0268960X16300492"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2017.01.002","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2017.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}